$ESMC
ESCALON MEDICAL CORP

2019 Q2 Form 10-K Financial Statement

#000086266819000010 Filed on September 27, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 2018 Q2
Revenue $2.281M $9.627M $2.750M
YoY Change -17.06% -15.57% -4.84%
Cost Of Revenue $1.116M $4.997M $1.510M
YoY Change -26.06% -20.67% -3.82%
Gross Profit $1.164M $4.629M $1.250M
YoY Change -6.86% -9.28% -5.3%
Gross Profit Margin 51.05% 48.09% 45.45%
Selling, General & Admin $970.5K $4.142M $1.060M
YoY Change -8.45% -5.8% -7.02%
% of Gross Profit 83.35% 89.48% 84.8%
Research & Development $199.0K $739.8K $110.0K
YoY Change 80.92% 47.85% -38.89%
% of Gross Profit 17.09% 15.98% 8.8%
Depreciation & Amortization $29.76K $50.14K $10.00K
YoY Change 197.6% 1.87% -50.0%
% of Gross Profit 2.56% 1.08% 0.8%
Operating Expenses $1.169M $4.882M $1.160M
YoY Change 0.82% -0.32% -12.12%
Operating Profit -$5.200K -$253.0K $90.00K
YoY Change -105.78% -223.56% 9663676415999900.0%
Interest Expense -$1.310K $17.35K -$30.00K
YoY Change -95.63% -86.19% 0.0%
% of Operating Profit -33.33%
Other Income/Expense, Net $0.00 $2.939K $0.00
YoY Change -99.22%
Pretax Income -$6.500K -$250.0K $50.00K
YoY Change -113.0% -142.84% -131.25%
Income Tax
% Of Pretax Income
Net Earnings -$250.0K -$250.0K $50.00K
YoY Change -600.03% -142.83% -131.25%
Net Earnings / Revenue -10.96% -2.6% 1.82%
Basic Earnings Per Share -$0.04
Diluted Earnings Per Share -$876.60 -$0.04 $4.252K
COMMON SHARES
Basic Shares Outstanding 7.415M shares 7.415M shares 7.415M shares
Diluted Shares Outstanding 7.415M shares

Balance Sheet

Concept 2019 Q2 2019 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $409.7K $409.7K $870.0K
YoY Change -52.9% -53.12% 61.11%
Cash & Equivalents $409.7K $409.7K $409.7K
Short-Term Investments
Other Short-Term Assets $223.1K $528.1K $249.6K
YoY Change -10.63% 5.71% 19.12%
Inventory $1.879M $1.879M $1.823M
Prepaid Expenses
Receivables $1.496M $1.496M $1.387M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $4.261M $4.313M $4.584M
YoY Change -7.05% -5.92% 10.32%
LONG-TERM ASSETS
Property, Plant & Equipment $67.90K $67.90K $76.27K
YoY Change -10.98% -10.97% 38.94%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $866.5K $814.6K $842.6K
YoY Change 2.84% -3.33% 1.67%
TOTAL ASSETS
Total Short-Term Assets $4.261M $4.313M $4.584M
Total Long-Term Assets $866.5K $814.6K $842.6K
Total Assets $5.127M $5.127M $5.427M
YoY Change -5.52% -5.52% 8.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $666.5K $666.5K $528.8K
YoY Change 26.03% 26.03% -49.51%
Accrued Expenses $656.7K $769.1K $762.0K
YoY Change -13.82% -12.04% 31.99%
Deferred Revenue $16.01K
YoY Change
Short-Term Debt $201.6K $201.6K $165.0K
YoY Change 22.17% 22.17% -34.0%
Long-Term Debt Due $3.400K $3.400K $0.00
YoY Change 7.94%
Total Short-Term Liabilities $2.260M $2.260M $2.247M
YoY Change 0.59% 0.59% -25.13%
LONG-TERM LIABILITIES
Long-Term Debt $14.90K $14.90K $20.00K
YoY Change -25.5% -17.41%
Other Long-Term Liabilities $690.1K $690.1K $750.0K
YoY Change -7.99% -7.92% -6.25%
Total Long-Term Liabilities $705.0K $705.0K $767.5K
YoY Change -8.15% -8.15% -3.98%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.260M $2.260M $2.247M
Total Long-Term Liabilities $705.0K $705.0K $767.5K
Total Liabilities $2.965M $2.965M $3.015M
YoY Change -1.64% -1.64% -20.68%
SHAREHOLDERS EQUITY
Retained Earnings -$68.19M -$67.94M
YoY Change 0.37% -0.85%
Common Stock $7.415K $7.415K
YoY Change 0.0% -1.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.162M $2.162M $2.412M
YoY Change
Total Liabilities & Shareholders Equity $5.127M $5.127M $5.427M
YoY Change -5.52% -5.52% 8.88%

Cashflow Statement

Concept 2019 Q2 2019 2018 Q2
OPERATING ACTIVITIES
Net Income -$250.0K -$250.0K $50.00K
YoY Change -600.03% -142.83% -131.25%
Depreciation, Depletion And Amortization $29.76K $50.14K $10.00K
YoY Change 197.6% 1.87% -50.0%
Cash From Operating Activities -$101.3K -$472.7K $30.00K
YoY Change -437.77% -542.84% -75.0%
INVESTING ACTIVITIES
Capital Expenditures -$15.61K -$22.12K -$30.00K
YoY Change -47.97% -47.14% 200.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$15.61K -$22.12K -$30.00K
YoY Change -47.97% -104.83% 200.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -810.0 $33.68K 10.00K
YoY Change -108.1% 124.55%
NET CHANGE
Cash From Operating Activities -101.3K -$472.7K 30.00K
Cash From Investing Activities -15.61K -$22.12K -30.00K
Cash From Financing Activities -810.0 $33.68K 10.00K
Net Change In Cash -117.7K -$461.1K 10.00K
YoY Change -1277.5% -179.52% -90.91%
FREE CASH FLOW
Cash From Operating Activities -$101.3K -$472.7K $30.00K
Capital Expenditures -$15.61K -$22.12K -$30.00K
Free Cash Flow -$85.72K -$450.6K $60.00K
YoY Change -242.87% -403.23% -53.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-06-30
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0000862668
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
7415329 shares
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2018Q4 dei Entity Public Float
EntityPublicFloat
356910 USD
CY2019 dei Entity Registrant Name
EntityRegistrantName
ESCALON MEDICAL CORP.
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019Q2 esmc Accruedinterestrelatedparty
Accruedinterestrelatedparty
112389 USD
CY2018 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
1407 USD
CY2019 esmc Increasedecreaseinliabilitiesofdiscontinuedoperations
Increasedecreaseinliabilitiesofdiscontinuedoperations
-1599 USD
CY2019 esmc Maximum Maturity Of Highly Liquid Investments Period
MaximumMaturityOfHighlyLiquidInvestmentsPeriod
P90D
CY2019 esmc Maximumincometaxrate
Maximumincometaxrate
0.35
CY2019 esmc Minimumincometaxrate
Minimumincometaxrate
0.21 USD
CY2019 esmc Operating Lease Square Footage
OperatingLeaseSquareFootage
3954 sqft
CY2018 esmc Pensionandpostretirementbenifitsobligationactuarialadjustments
Pensionandpostretirementbenifitsobligationactuarialadjustments
52024 USD
CY2019 esmc Pensionandpostretirementbenifitsobligationactuarialadjustments
Pensionandpostretirementbenifitsobligationactuarialadjustments
42505 USD
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
528844 USD
CY2018Q2 us-gaap Cash
Cash
1124002 USD
CY2019Q2 us-gaap Cash
Cash
662878 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
544118 USD
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
874002 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
409743 USD
CY2017Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
544118 USD
CY2018Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1124002 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
662878 USD
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
579884 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-461124 USD
CY2019 us-gaap Common Stock Conversion Basis
CommonStockConversionBasis
4300000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
666510 USD
CY2018Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1387133 USD
CY2019Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1496105 USD
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
762032 USD
CY2019Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
656707 USD
CY2018Q2 us-gaap Accrued Rent Current And Noncurrent
AccruedRentCurrentAndNoncurrent
49458 USD
CY2018Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
797459 USD
CY2019Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
827948 USD
CY2018Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2019Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
69702043 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
0 USD
CY2018 us-gaap Advertising Expense
AdvertisingExpense
27000 USD
CY2019 us-gaap Advertising Expense
AdvertisingExpense
33000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
0 USD
CY2017Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
172120 USD
CY2018Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
118930 USD
CY2019Q2 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
110507 USD
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
45593 USD
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
5450 USD
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
7597 USD
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
2973 USD
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
367500 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4986120 shares
CY2018Q2 us-gaap Assets
Assets
5426793 USD
CY2019Q2 us-gaap Assets
Assets
5127438 USD
CY2018Q2 us-gaap Assets Current
AssetsCurrent
4584169 USD
CY2019Q2 us-gaap Assets Current
AssetsCurrent
4312836 USD
CY2017Q2 us-gaap Cash
Cash
544118 USD
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000 shares
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2019Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7415329 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
7415329 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2019Q2 us-gaap Common Stock Value
CommonStockValue
7415 USD
CY2019 us-gaap Common Stock Voting Rights
CommonStockVotingRights
0.7781
CY2018 us-gaap Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
0.11
CY2019 us-gaap Concentration Risk Credit Risk Financial Instruments
ConcentrationRiskCreditRiskFinancialInstruments
0.10
CY2019 us-gaap Concentration Risk Customer
ConcentrationRiskCustomer
0.1
CY2019Q1 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
51600 USD
CY2019Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
2.15 shares
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
6299720 USD
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4997461 USD
CY2018 us-gaap Costs And Expenses
CostsAndExpenses
11197552 USD
CY2019 us-gaap Costs And Expenses
CostsAndExpenses
9879618 USD
CY2018 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0 USD
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Customer Deposits Current
CustomerDepositsCurrent
61494 USD
CY2018 us-gaap Deferred Compensation Arrangement With Individual Distribution Paid
DeferredCompensationArrangementWithIndividualDistributionPaid
101891 USD
CY2019 us-gaap Deferred Compensation Arrangement With Individual Distribution Paid
DeferredCompensationArrangementWithIndividualDistributionPaid
101891 USD
CY2018 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-3498532 USD
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
44287 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2018Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
160935 USD
CY2019Q2 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
156808 USD
CY2017Q2 us-gaap Deferred Revenue
DeferredRevenue
388434 USD
CY2018Q1 us-gaap Deferred Revenue
DeferredRevenue
481180 USD
CY2018Q2 us-gaap Deferred Revenue
DeferredRevenue
481180 USD
CY2019Q2 us-gaap Deferred Revenue
DeferredRevenue
426804 USD
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
968971 USD
CY2019 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
887980 USD
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
481180 USD
CY2019Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
426803 USD
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
876225 USD
CY2019 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
942356 USD
CY2018 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-999581 USD
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
12653 USD
CY2018Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7723651 USD
CY2019Q2 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
7776465 USD
CY2018Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2019Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2018Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
160935 USD
CY2019Q2 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
156808 USD
CY2018Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7042134 USD
CY2019Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
7102298 USD
CY2018Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
119980 USD
CY2019Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
704990 USD
CY2019Q2 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
127642 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
207698 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Credit Carryforwards General Business
DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness
207698 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
46527 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
40565 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
178788 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Postretirement Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsPostretirementBenefits
166317 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
24975 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts
23207 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
96813 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
102002 USD
CY2018Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
6736 USD
CY2019Q2 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Warranty Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsWarrantyReserves
6736 USD
CY2018Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7562716 USD
CY2019Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
7619657 USD
CY2018Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
160935 USD
CY2019Q2 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
156808 USD
CY2018Q2 us-gaap Defined Benefit Plan Assumptions Used Calculating Benefit Obligation Discount Rate
DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
0.045
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
49218 USD
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
50139 USD
CY2018Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.01
CY2019Q2 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.0355
CY2018Q1 us-gaap Dividends Payable Amount Per Share
DividendsPayableAmountPerShare
0.03
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2018 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2018 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.34
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.21
CY2018 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
-0.0051
CY2019 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.3349
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0
CY2018Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
424871 USD
CY2019Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.3670
CY2018Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
400 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
0 USD
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
161350 USD
CY2019Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
141700 USD
CY2018Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
143330 USD
CY2019Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
149835 USD
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
500000 USD
CY2019 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
0 USD
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-518619 USD
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
137666 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-149827 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
103522 USD
CY2018 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
237930 USD
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-105325 USD
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
92745 USD
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-54377 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-94524 USD
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
55446 USD
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
59162 USD
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
0 USD
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
40076 USD
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25373 USD
CY2018 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-49867 USD
CY2019 us-gaap Increase Decrease In Pension And Postretirement Obligations
IncreaseDecreaseInPensionAndPostretirementObligations
-59386 USD
CY2018 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
1590411 shares
CY2019 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2018Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
605006 USD
CY2019Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
605006 USD
CY2018 us-gaap Interest Expense
InterestExpense
125687 USD
CY2019 us-gaap Interest Expense
InterestExpense
17353 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
59162 USD
CY2019 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
0 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
37811 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
44315 USD
CY2018Q2 us-gaap Interest Payable Current
InterestPayableCurrent
112389 USD
CY2019Q2 us-gaap Interest Payable Current
InterestPayableCurrent
112389 USD
CY2018Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
978514 USD
CY2019Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
778621 USD
CY2018Q2 us-gaap Inventory Net
InventoryNet
1823414 USD
CY2019Q2 us-gaap Inventory Net
InventoryNet
1878860 USD
CY2018Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
652613 USD
CY2019Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
874985 USD
CY2018Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
192287 USD
CY2019Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
225254 USD
CY2018 us-gaap Investment Income Interest
InvestmentIncomeInterest
4642 USD
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
9170 USD
CY2018Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
28549 USD
CY2019Q2 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
28549 USD
CY2018Q2 us-gaap Liabilities
Liabilities
3014538 USD
CY2019Q2 us-gaap Liabilities
Liabilities
2965199 USD
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5426793 USD
CY2019Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5127438 USD
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2247021 USD
CY2019Q2 us-gaap Liabilities Current
LiabilitiesCurrent
2260209 USD
CY2018Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
767517 USD
CY2018Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
92532 USD
CY2019Q2 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
90933 USD
CY2018Q2 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
165000 USD
CY2019Q2 us-gaap Line Of Credit Facility Fair Value Of Amount Outstanding
LineOfCreditFacilityFairValueOfAmountOutstanding
201575 USD
CY2019Q2 us-gaap Line Of Credit Facility Interest Rate At Period End
LineOfCreditFacilityInterestRateAtPeriodEnd
0.0624
us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
36849 USD
CY2019 us-gaap Line Of Credit Facility Periodic Payment Interest
LineOfCreditFacilityPeriodicPaymentInterest
17353 USD
CY2018Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
701848 USD
CY2019Q2 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
717460 USD
CY2018 us-gaap Multiemployer Plans Plan Contributions1
MultiemployerPlansPlanContributions1
0 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33682 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
458148 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-22117 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
106736 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-472689 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
583675 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-250016 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-250016 USD
CY2018 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
564307 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-301616 USD
CY2018 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
583675 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-250016 USD
CY2018 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
564307 USD
CY2019 us-gaap Net Income Loss From Continuing Operations Available To Common Shareholders Basic
NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic
-301616 USD
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
378955 USD
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2939 USD
CY2018 us-gaap Notes Assumed1
NotesAssumed1
22372 USD
CY2019 us-gaap Notes Assumed1
NotesAssumed1
0 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
204720 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-252955 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1360981 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
356414 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
189790 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
188755 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
256311 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
272881 USD
CY2019Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
96830 USD
CY2018Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
59795 USD
CY2018Q2 us-gaap Other Assets Current
OtherAssetsCurrent
249620 USD
CY2019Q2 us-gaap Other Assets Current
OtherAssetsCurrent
274993 USD
us-gaap Other Income
OtherIncome
500000 USD
CY2018Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
18037 USD
CY2019Q2 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
14896 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
500000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
11122 USD
CY2018Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
3153 USD
CY2019Q2 us-gaap Other Notes Payable Current
OtherNotesPayableCurrent
3401 USD
CY2018 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
12500 USD
CY2019 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
0 USD
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
29352 USD
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
22117 USD
CY2017Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
901238 USD
CY2018Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
851371 USD
CY2019Q2 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Current And Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesCurrentAndNoncurrent
791985 USD
CY2018 us-gaap Pension And Other Postretirement Benefit Contributions
PensionAndOtherPostretirementBenefitContributions
8491 USD
CY2018Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
101891 USD
CY2019Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Current Liabilities
PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
101891 USD
CY2018Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
749480 USD
CY2019Q2 us-gaap Pension And Other Postretirement Defined Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
690094 USD
CY2018 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
19368 USD
CY2019 us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
70968 USD
CY2018 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
19368 USD
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
51600 USD
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2018Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2019Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
2000000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2019Q2 us-gaap Preferred Stock Value
PreferredStockValue
645000 USD
CY2018 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
100000 USD
CY2019 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0 USD
CY2018 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
-85000 USD
CY2019 us-gaap Proceeds From Repayments Of Lines Of Credit
ProceedsFromRepaymentsOfLinesOfCredit
36575 USD
CY2018Q2 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
32078 USD
CY2018Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
873727 USD
CY2019Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
895844 USD
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
76268 USD
CY2019Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
67896 USD
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-53190 USD
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-5450 USD
CY2017Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
545000 USD
CY2018Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
100000 USD
CY2018Q2 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
645000 USD
CY2019Q2 us-gaap Related Party Transaction Due From To Related Party
RelatedPartyTransactionDueFromToRelatedParty
0 USD
CY2018Q3 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.0125
CY2018Q3 us-gaap Repayments Of Lines Of Credit
RepaymentsOfLinesOfCredit
201575 USD
CY2018 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2019 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
2893 USD
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.78
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
367500 shares
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
500334 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
739765 USD
CY2017Q2 us-gaap Restricted Cash
RestrictedCash
0 USD
CY2018Q2 us-gaap Restricted Cash
RestrictedCash
250000 USD
CY2019Q2 us-gaap Restricted Cash
RestrictedCash
253135 USD
CY2018Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
250000 USD
CY2019Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
253135 USD
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-67942203 USD
CY2019Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68192219 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11402272 USD
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
9626663 USD
CY2018Q2 us-gaap Sales And Excise Tax Payable Current And Noncurrent
SalesAndExciseTaxPayableCurrentAndNoncurrent
104539 USD
CY2018 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4397498 USD
CY2019 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4142392 USD
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
0 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
213000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
213000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.48
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
134500 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
154500 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
502000 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
367500 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
213000 shares
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
213000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.12
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.78
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.48
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.05
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.21
CY2018 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.00
CY2018Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
165000 USD
CY2019Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
201575 USD
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
645000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
1183580 USD
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
2412255 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
2162239 USD
CY2018 us-gaap Treasury Stock Retired Par Value Method Amount
TreasuryStockRetiredParValueMethodAmount
0 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4498113 USD
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-56941 USD
CY2018 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
9141468 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7415329 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7551057.0 shares
CY2018 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7551057 shares
CY2019 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7415329 shares
CY2019 us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;Escalon Medical Corp. ("Escalon" or "Company") is a Pennsylvania corporation initially incorporated in California in 1987, and reincorporated in Pennsylvania in November 2001. Within this document, the &#8220;Company&#8221; collectively shall mean Escalon, which includes its division called "Trek" and its wholly owned subsidiaries: Sonomed, Inc. (&#8220;Sonomed&#8221;), Escalon Digital Solutions, Inc. (&#8220;EMI&#8221;), Escalon Holdings, Inc. (&#8220;EHI&#8221;), Escalon IP Holdings, Inc., and Sonomed IP Holdings, Inc. </font></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;"></font><font style="font-family:inherit;font-size:10pt;">The Company operates in the healthcare market, specializing in the development, manufacture, marketing and distribution of medical devices and pharmaceuticals in the area of ophthalmology. The Company and its products are subject to regulation and inspection by the United States Food and Drug Administration (the &#8220;FDA&#8221;). The FDA and other government authorities requires extensive testing of new products prior to sale and has jurisdiction over the safety, efficacy and manufacture of products, as well as product labeling and marketing.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Company&#8217;s common stock trades on the OTCQB Market under the symbol &#8220;ESMC.&#8221;</font></div></div>
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with accounting principles generally affected in the United States of America ("US GAAP") requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0000862668-19-000010-index-headers.html Edgar Link pending
0000862668-19-000010-index.html Edgar Link pending
0000862668-19-000010.txt Edgar Link pending
0000862668-19-000010-xbrl.zip Edgar Link pending
esmc-20190630.xml Edgar Link completed
esmc-20190630.xsd Edgar Link pending
esmc-20190630_cal.xml Edgar Link unprocessable
esmc-20190630_def.xml Edgar Link unprocessable
esmc-20190630_lab.xml Edgar Link unprocessable
esmc-20190630_pre.xml Edgar Link unprocessable
esmc_20190630-10kex231.htm Edgar Link pending
esmc_20190630-10kex311.htm Edgar Link pending
esmc_20190630-10kex312.htm Edgar Link pending
esmc_20190630-10kex321.htm Edgar Link pending
esmc_20190630-10kex322.htm Edgar Link pending
esmc_2019630-10k.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending